Find Your Way Forward Explore the AdaptDx Pro and Theiafrom the comfort of your home or office.Visit our Virtual Exhibit
The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
The advanced technology of the AdaptDx Pro™ can enhance your ability to diagnose AMD at the subclinical stage and manage this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
MacuLogix is launching its AdaptDx Pro device, which will be distributed in Australia by Optos pending Therapeutic Goods Administration approval.
Paul M. Karpecki, OD, dives into replacing or upgrading tests patients and staff dislike to ones that benefit everyone.
Craig Bowen, OD, (owner of Tualatin Eye Associates) discusses how change is often necessary in order to grow one's practice.